Moreover, the TIDE algorithm was applied to predict the potential ICB response among HCC patients with varying levels of Gal1 expression.[33] The results suggested that those with low Gal1 expression might exhibit a more favorable response to anti‐PD‐1 therapy (Figure 6A). This evidence concerns the gene LGALS1 and hepatocellular carcinoma.